Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04442724 · ClinicalTrials.gov registry record · NA
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
A NA study of Bladder Cancer and Neoplasms, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT04442724 is a NA study of Bladder Cancer and Neoplasms that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 60 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04442724, a NA study of Bladder Cancer and Neoplasms, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI imaging technology can help with detection of bladder cancer earlier and more accurately when evidence of bladder cancer is not visible by scope.
Conditions Studied
Interventions
- PROCEDURE Fiducial marker placement
- DIAGNOSTIC_TEST Multiparametric MRI (mpMRI)
Study Locations (3)
California
- Cedars-Sinai Medical Center (CSMC) - Los Angeles
- University of California Los Angeles - Los Angeles
Massachusetts
- Harvard School of Medicine/Massachusetts General Hospital (MGH) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04442724
The ClinicalTrials.gov registry entry for NCT04442724 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fiducial marker placement is the first listed.
NCT04442724 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04442724 about?
NCT04442724 is a clinical study titled "Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy". The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI ...
What is the current status of trial NCT04442724?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2020-07-01. Estimated completion is 2026-06-30.
What conditions does trial NCT04442724 study?
This clinical trial studies the following conditions: Bladder Cancer, Neoplasms, Urologic Neoplasms, Urinary Bladder Neoplasm, Urinary Bladder Diseases.
What interventions are being tested in trial NCT04442724?
The interventions under investigation include: Fiducial marker placement (PROCEDURE), Multiparametric MRI (mpMRI) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04442724?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04442724 being conducted?
This trial has 3 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.